Tags: Vaccines | effective | Chlamydia | vaccine | STI | infection

Researchers Developing Effective Chlamydia Vaccine

Image: Researchers Developing Effective Chlamydia Vaccine
(Copyright iStock)

Thursday, 21 Jul 2016 08:52 AM

Researchers at McMaster University, Canada, have presented the first promising steps towards a vaccine against chlamydia, a "silent" sexually transmitted infection (STI) that affects 113 million people worldwide each year and which can lead to infertility.

The research, published in the journal Vaccine, could help protect people all over the world from chlamydia. This common and serious STI is transmitted via unprotected oral, anal and vaginal sex, and often goes untreated because it has no symptoms. It's therefore known as a "silent" infection. If left untreated, chlamydia can cause upper genital tract infections, pelvic inflammatory disease and infertility.

The paper reveals the first steps towards developing a low-cost vaccine providing effective protection against the disease and combating the effects of associated pathologies. "Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections," said David Bulir, co-author of the study.

The scientists identified a chlamydia antigen, BD584, that reduced chlamydial shedding, a symptom of the disease, by 95%. The antigen also reduced hydrosalpinx by 87.5%, a symptom causing the fallopian tubes to block with serous fluid and which can lead to infertility.

"Not only is the vaccine effective," explains co-author Steven Liang, "it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma." Trachoma is an eye infection caused by chlamydia that can lead to blindness. It affects millions of people worldwide.

"The vaccine would be administered through the nose. This is easy and painless and does not require highly trained health professionals to administer," he concluded.

The next step for the scientists is to continue testing the effectiveness of the vaccine against different strains of chlamydia and in different formulations.

Humans are mainly affected by three main strains of chlamydia: Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci, responsible for pneumonia and respiratory diseases.

Chlamydia trachomatis bacteria can also be transmitted by sharing sex toys and through the exchange of body fluids. It is rarely transmitted via cunnilingus. Chlamydia can, however, be passed to newborn babies by infected mothers during childbirth.

In three out of four cases, the disease affects young adults aged between 15 and 24 years old.

© AFP/Relaxnews 2017

 
1Like our page
2Share
Health-News
Researchers at McMaster University, Canada, have presented the first promising steps towards a vaccine against chlamydia, a silent sexually transmitted infection (STI) that affects 113 million people worldwide each year and which can lead to infertility. The research,...
effective, Chlamydia, vaccine, STI, infection
388
2016-52-21
Thursday, 21 Jul 2016 08:52 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved